FDA Multiple Myeloma Approval Gives Fresh Catalyst To Johnson & Johnson

The FDA approved a new DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients who are not eligible ...
Fierce Pharma

J&J sharpens Darzalex's edge with quadruplet FDA nod in newly diagnosed multiple myeloma

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
CURE

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
BioSpace

J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
The American Journal of Managed Care

FDA Greenlights D-VRd Quadruplet for Newly Diagnosed Multiple Myeloma

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...
Frontiers

Genetics of Multiple Myeloma: from Diagnosis to Treatment

Multiple Myeloma (MM) research is at the forefront of personalized medicine, driven by rapid advancements in laboratory genomics and molecular diagnostics.
PharmExec

FDA Approves Darzalex Faspro-Based Quadruplet Regimen for Adults with Newly Diagnosed Multiple Myeloma

FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple ...
CURE

A Message of Hope for the Newly Diagnosed Myeloma Patient

Discover inspiring messages of hope from cancer survivors, emphasizing resilience, scientific advancements, and the ...
Pharmabiz

Johnson & Johnson’s Darzalex Faspro-based quadruplet regimen approved in US for newly diagnosed patients with multiple myeloma who are transplant ineligible

Johnson & Johnson’s Darzalex Faspro-based quadruplet regimen approved in US for newly diagnosed patients with multiple myeloma who are transplant ineligible: Horsham, Pennsylvan ...
The Manila Times

The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of Directors

The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of ...
Cancer Therapy Advisor

Darzalex Faspro Quadruplet Tx Approved for Transplant-Ineligible Multiple Myeloma

Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.